Form 4: Immunome Inc. Director Acquires Stock Options
SEC Form 4 Filing
Director Isaac Barchas acquired 11,333 stock options in Immunome Inc. on June 13, 2024.
Summary
- On June 13, 2024, Isaac Barchas, a director of Immunome Inc., acquired 11,333 stock options.
- The exercise price of these options is $16.04.
- The options vest in four quarterly installments starting June 13, 2024, and continuing until the one-year anniversary, subject to continued service with the company.
- Following the transaction, Barchas directly owns 11,333 derivative securities.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants to a director, indicating neither significant positive nor negative implications.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency regarding the holdings of company insiders.
Stakeholder Impact
- The acquisition of stock options by a director may have a minor positive impact on shareholder sentiment, as it can signal confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 06/13/2024 | Date of earliest transaction: Isaac Barchas acquired stock options. |
| 06/13/2024 | Options vest in 4 quarterly installments, commencing from this date. |
| 06/12/2034 | Expiration date of the stock options. |
| 06/18/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.